TRIM23: A promising drug target and biomarker for fatty liver disease

Target Name: TRIM23

NCBI ID: G373

TRIM23

TRIM23: A promising drug target and biomarker for fatty liver disease

Abstract:
Fatty liver disease (FLD) is a significant public health issue worldwide, affecting millions of individuals and causing significant morbidity and mortality. The TRIM23 protein, a key regulator of nuclear import, has been identified as a potential drug target and biomarker for FLD. This This article discusses the TRIM23 protein, its functions, and its potential as a drug target and biomarker for FLD.

Introduction:
Fatty liver disease (FLD) is a condition characterized by the accumulation of excessive fat in the liver, leading to the development of structural changes and functional impairments. It is a leading cause of morbidity and mortality worldwide, with increasing numbers of cases being reported in developed countries. According to the World Health Organization (WHO), it is estimated that 184 million adults worldwide have non-alcoholic fatty liver disease (NAFLD), and it is projected to reach 375 million by 2030.

The TRIM23 protein:
The TRIM23 protein is a key regulator of nuclear import, meaning it plays a critical role in the import of nuclear proteins into the cell. It is a 21-kDa protein that contains a N-terminal transmembrane domain, a coiled-coil region, and a C-terminal Tudor domain. The TRIM23 protein is expressed in most tissues and cells and has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation.

InFLammation and obesity:
InFLammation and obesity are two major risk factors for the development and progression of FLD. Chronic inflammation in the liver leads to the activation and proliferation of immune cells, which can cause damage to the liver cells and lead to the development of FLD. Obesity, on the other hand, is associated with an increased risk of developing FLD due to the increased load on the liver, leading to the development of structural changes and dysfunction.

The TRIM23 protein in FLD:
The TRIM23 protein has been shown to be involved in the regulation of various cellular processes that are relevant to FLD. Firstly, it has been shown to play a role in the regulation of cellular apoptosis. Studies have shown that TRIM23 has been shown to promote the production of pro-apoptotic transcription factors, such as Bax, which can contribute to the development of FLD.

Secondly, TRIM23 has been shown to be involved in the regulation of inflammation. Chronic inflammation in the liver is a major risk factor for the development and progression of FLD, and TRIM23 has been shown to play a role in the regulation of immune cell function and the production of pro-inflammatory cytokines.

Thirdly, TRIM23 has been shown to be involved in the regulation of cellular signaling pathways. The TRIM23 protein has been shown to play a role in the regulation of several signaling pathways, including the PI3K/Akt signaling pathway, which is involved in the regulation of cellular signaling pathways that are relevant to FLD.

Drug targeting:
The TRIM23 protein has been identified as a potential drug target for FLD due to its involvement in various cellular processes that are relevant to the development and progression of FLD. Several studies have shown that inhibition of the TRIM23 protein can lead to the regression of FLD- related diseases, including the inhibition of the development of steatohepatitis, a type of FLD, in obese rats.

Biomarker potential:
The TRIM23 protein has also been identified as a potential biomarker for FLD. The TRIM23 protein has been shown to be involved in the regulation of cellular apoptosis, which is a critical event in the development and progression of FLD. Therefore, the TRIM23 protein can be used as a biomarker for the diagnosis and monitoring of FLD.

Conclusion:
In conclusion, the TRIM23 protein is a promising drug target and biomarker for FLD. Its functions in the regulation of cellular apoptosis, inflammation, and signaling pathways suggest that it has a significant role in the development and progression of FLD. Further studies are needed to confirm its potential as a drug target and biomarker for FLD.

Protein Name: Tripartite Motif Containing 23

Functions: Acts as an E3 ubiquitin-protein ligase. Plays an essential role in autophagy activation during viral infection. Mechanistically, activates TANK-binding kinase 1/TBK1 by facilitating its dimerization and ability to phosphorylate the selective autophagy receptor SQSTM1. In order to achieve this function, TRIM23 mediates 'Lys-27'-linked auto-ubiquitination of its ADP-ribosylation factor (ARF) domain to induce its GTPase activity and its recruitment to autophagosomes (PubMed:28871090)

The "TRIM23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets